Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms

Published:2019-03-04 Issue:4 Volume:129 Page:1596-1611
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Stivala Simona^ORCID,Codilupi Tamara^ORCID,Brkic Sime,Baerenwaldt Anne,Ghosh Nilabh,Hao-Shen Hui,Dirnhofer Stephan,Dettmer Matthias S.^ORCID,Simillion Cedric^ORCID,Kaufmann Beat A.,Chiu Sophia^ORCID,Keller Matthew,Kleppe Maria,Hilpert Morgane,Buser Andreas S.,Passweg Jakob R.,Radimerski Thomas,Skoda Radek C.,Levine Ross L.,Meyer Sara C.

Funder

Swiss National Science Foundation

Swiss Cancer League/Swiss Cancer Research

Foundation for the Fight against Cancer

Foundation Peter-Anton and Anna-Katharina Miescher and the Swiss Society of Hematology

Nora van Meeuwen-Häfliger Foundation

National Cancer Institute

National Institutes of Health

LLS

MSKCC Support Grant/Core Grant

as indicated in the list below

Swiss Bridge Foundation

Dr. Arnold U. und Susanne Huggenberger-Bischoff Stiftung zur Krebsforschung

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/98785/files/pdf

Reference80 articles.

1. Myeloproliferative Neoplasms

2. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

3. Allogeneic Stem Cell Transplantation in Myelofibrosis

4. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

5. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms;Frontiers in Pharmacology;2024-07-22

2. Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms;Frontiers in Oncology;2024-07-18

3. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis;Dermatology and Therapy;2024-06-19

4. Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer;Medicinal Research Reviews;2024-05-20

5. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives;Blood Cancer Journal;2024-04-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3